Balanced news tone
News Sentiment
APRE sentiment intelligence
Aprea Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
56 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+0.5% over one week, +8.6% over four weeks, trend inactive, and below fair value.
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
0.5%
Price digesting
Trend fit
Trend inactive
8.6% over four weeks
Fair value
-74.4%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
33
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Stocktwits
Direct company coverage
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 23:28
- Source
- Stocktwits
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE
This article provides financial information for Aprea Therapeutics, Inc. (NASDAQ: APRE), specifically detailing its Enterprise Value to EBITDA forward. It lists various data providers for market and reference data, along with several copyright notices. The content appears to be a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:39
- Source
- TradingView
Finviz
Direct company coverage
APRE - Aprea Therapeutics Inc Volatility & Greeks
This article provides a detailed financial snapshot of Aprea Therapeutics Inc (APRE), including its latest stock performance, key financial metrics, volatility, and various fundamental and technical indicators. It covers share statistics, profitability ratios, earnings per share,
- Tone
- Negative 42/100
- Event
- Earnings
- Published
- 04 Jul 2026 10:41
- Source
- Finviz
TradingView
Direct company coverage
APRE Forecast — Price Target — Prediction for 2027
This article provides an overview of Aprea Therapeutics, Inc. (APRE) stock, including its current price, analyst price targets, and historical performance. It details earnings, revenue, market capitalization, and various financial metrics such as EBITDA and volatility. The articl
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:09
- Source
- TradingView
TradingView
Direct company coverage
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE)
This article provides an overview of Aprea Therapeutics, Inc. (NASDAQ: APRE) stock, including its current price, historical performance, and analyst forecasts. It also details financial data such as market capitalization, earnings per share, revenue, and net income, alongside inf
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 26 Jun 2026 15:40
- Source
- TradingView
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk
Aprea Therapeutics Inc (APRE) has a current risk assessment score of 2.31, ranking 222 out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.46 indicates higher volatility compared to the S&P 500. The article details APRE's volatility, drawdown, and
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 23 Jun 2026 07:40
- Source
- TradingKey
Stock Titan
Direct company coverage
[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity
Aprea Therapeutics director Gabriela Gruia received new equity compensation on June 16, 2026, including 3,135 restricted stock units and stock options for 12,555 shares at an exercise price of $0.7293. These grants will vest in full on June 16, 2027, contingent on her continued s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 19:40
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
Aprea Shareholders Approve Directors, Reverse Split Flexibility
Aprea Therapeutics shareholders recently approved the election of three Class I directors and ratified the appointment of EisnerAmper LLP as their independent public accounting firm. They also authorized an amendment to the company's certificate of incorporation to allow for a re
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 04:39
- Source
- The Globe and Mail
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Institutional Confidence
The article analyzes the institutional confidence score for Aprea Therapeutics Inc (APRE), which currently stands at 3.00, placing it 193 out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 46.24% quarter-over-qu
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 15:40
- Source
- TradingKey
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Aprea Therapeutics Inc (APRE), noting its current valuation score is 8.36, ranking 144th out of 388 in the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio and mentions that relevant data for P
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:38
- Source
- TradingKey
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aprea Therapeutics Inc (APRE), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests the stock is currently in a range-boun
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 18 Jun 2026 05:38
- Source
- TradingKey
Minichart
Direct company coverage
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting
Aprea Therapeutics shareholders have approved a reverse stock split authorization, allowing the Board of Directors to enact a split ratio between 1-for-3 and 1-for-8. This decision, along with the election of three Class I directors and other key proposals, was made during the 20
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 04:38
- Source
- Minichart
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aprea Therapeutics Inc (APRE) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have an average price target of $10.50 for APRE, with a strong buy rating based on four analyses. The company's expected revenue for th
- Tone
- Positive 79/100
- Event
- Earnings
- Published
- 18 Jun 2026 02:38
- Source
- TradingKey
Investing.com Nigeria
Direct company coverage
Aprea Therapeutics shareholders approve director elections and reverse stock split
Aprea Therapeutics shareholders have approved the election of three Class I directors and ratified EisnerAmper LLP as their independent registered accounting firm. Additionally, shareholders approved a reverse stock split at a ratio between one-for-three and one-for-eight, along
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 00:08
- Source
- Investing.com Nigeria
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey focuses on Aprea Therapeutics Inc (APRE) and its revenue breakdown. However, it explicitly states that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. The page provides gener
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 17:10
- Source
- TradingKey
TradingKey
Direct company coverage
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Aprea Therapeutics Inc (APRE), listing major individual and institutional holders along with their proportional ownership. It provides a breakdown of shareholder types such as individual investors, private equity, and hedge funds,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 17:10
- Source
- TradingKey
TradingView
Direct company coverage
APRE: All agenda items, including director elections and reverse stock split, were approved
Aprea Therapeutics (APRE) stockholders approved all agenda items during their 2026 Annual General Meeting. These items included director elections, auditor ratification, a reverse stock split, and executive compensation. Final voting results will be disclosed in a Form 8-K.
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 16 Jun 2026 14:40
- Source
- TradingView
Quartr
Direct company coverage
Aprea Therapeutics (APRE) AGM 2026 Summary
Aprea Therapeutics (APRE) held its 2026 Annual General Meeting virtually on June 16, 2026. The agenda included elections for three directors, auditor ratification, authorization for a reverse stock split, executive compensation approval, and determination of say-on-pay frequency.
- Tone
- Positive 64/100
- Event
- Regulatory and legal
- Published
- 16 Jun 2026 14:40
- Source
- Quartr
Moomoo
Direct company coverage
Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5
Oppenheimer has initiated coverage on Aprea Therapeutics (APRE.US) with a Buy rating. The firm has also set a target price of $5 for the stock. This news suggests a positive outlook from Oppenheimer regarding Aprea Therapeutics' future performance.
- Tone
- Positive 76/100
- Event
- Analyst action
- Published
- 15 Jun 2026 15:40
- Source
- Moomoo
Finviz
Direct company coverage
APRE - Aprea Therapeutics Inc Stock Price and Quote
This page provides a detailed financial overview and news updates for Aprea Therapeutics Inc (APRE). It includes current stock price, financial metrics, analyst ratings, insider transactions, and a timeline of corporate announcements and clinical trial updates, particularly conce
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 03 Jun 2026 22:10
- Source
- Finviz
Moomoo
Direct company coverage
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2
H.C. Wainwright has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its target price at $1.2. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.
- Tone
- Positive 76/100
- Event
- Analyst action
- Published
- 01 Jun 2026 21:10
- Source
- Moomoo
BriefGlance
Direct company coverage
Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers
Aprea Therapeutics has announced promising early data from a Phase 1 trial of its novel WEE1 inhibitor, APR-1051, for advanced solid tumors. The drug showed anti-tumor activity, with partial tumor shrinkage in endometrial cancer patients and disease stabilization in others, along
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 01 Jun 2026 13:39
- Source
- BriefGlance
The Manila Times
Direct company coverage
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The study, ACESOT-1051, reported partial responses and stable disease in heavily pretreated p
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 01 Jun 2026 12:39
- Source
- The Manila Times
Stock Titan
Direct company coverage
Cancer trial drug APR-1051 posts partial responses at ASCO 2026
Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The ACESOT-1051 study reported partial responses in two endometrial cancer patients and stabl
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:10
- Source
- Stock Titan
dars.gov.et
Direct company coverage
Aprea Therapeutics (APRE) Gains 2.78% as Shares Approach Key Resistance at $0.99 - Day Trade Opportunities
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- dars.gov.et
MSN
Direct company coverage
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know
This article announces that Aprea Therapeutics (APRE) has received an upgraded "buy" rating. It suggests that investors should be aware of this development.
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 23 May 2026 14:09
- Source
- MSN
TradingView
Direct company coverage
Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing
Aprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 16 May 2026 01:08
- Source
- TradingView
Stock Titan
Direct company coverage
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE)
Vestal Point Capital and Ryan Wilder have disclosed a 9.9% beneficial ownership stake in Aprea Therapeutics (NASDAQ: APRE) via a Schedule 13G filing. This stake, totaling 22,654,832 shares, predominantly includes shares issuable upon the exercise of warrants, some of which are su
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 May 2026 00:08
- Source
- Stock Titan